Skip to main content

Axid Pulvules Side Effects

Generic name: nizatidine

Medically reviewed by Drugs.com. Last updated on Apr 27, 2023.

Note: This document contains side effect information about nizatidine. Some dosage forms listed on this page may not apply to the brand name Axid Pulvules.

Applies to nizatidine: oral capsule, oral tablet.

Serious side effects of Axid Pulvules

Along with its needed effects, nizatidine (the active ingredient contained in Axid Pulvules) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking nizatidine:

More common

Less common

Rare

Incidence not known

Other side effects of Axid Pulvules

Some side effects of nizatidine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

Rare

For Healthcare Professionals

Applies to nizatidine: oral capsule, oral solution, oral tablet.

General

The most commonly reported side effects included headache, rhinitis, abdominal pain, and diarrhea.[Ref]

Nervous system

Very common (10% or more): Headache (up to 16.6%)

Common (1% to 10%): Dizziness, somnolence

Frequency not reported: Seizure[Ref]

A pediatric patient given 2.5 mg/kg orally 2 times a day for 23 days experienced an EEG-diagnosed seizure during treatment.[Ref]

Gastrointestinal

Common (1% to 10%): Constipation, diarrhea, dry mouth, dyspepsia, flatulence, gastrointestinal disorder, nausea, nausea and vomiting, tooth disorder, vomiting[Ref]

Respiratory

Common (1% to 10%): Cough, cough increased, nasal congestion, nasopharyngitis, pharyngitis, rhinitis, sinusitis

Postmarketing reports: Bronchospasm, laryngeal edema[Ref]

Other

Common (1% to 10%): Accident, asthenia, fever, injury, pain, pyrexia, surgical procedure[Ref]

Psychiatric

Common (1% to 10%): Abnormal dreams, anxiety, insomnia, irritability, nervousness

Postmarketing reports: Decreased libido, reversible mental confusion[Ref]

Dermatologic

Common (1% to 10%): Pruritus, rash, sweating, urticaria

Postmarketing reports: Exfoliative dermatitis[Ref]

Musculoskeletal

Common (1% to 10%): Back pain, myalgia

Postmarketing reports: Arthralgia[Ref]

Immunologic

Common (1% to 10%): Infection

Rare (0.01% to 0.1%): Serum sickness, serum sickness-like reactions[Ref]

Cardiovascular

Common (1% to 10%): Chest pain

Frequency not reported: Short episodes of asymptomatic ventricular tachycardia

Postmarketing reports: Vasculitis[Ref]

Metabolic

Common (1% to 10%): Anorexia

Postmarketing reports: Hyperuricemia unrelated to gout or nephrolithiasis[Ref]

Ocular

Common (1% to 10%): Amblyopia[Ref]

Hematologic

Uncommon (0.1% to 1%): Anemia

Postmarketing reports: Agranulocytosis, eosinophilia, fatal thrombocytopenia, leukopenia, thrombocytopenic purpura[Ref]

Fatal thrombocytopenia was reported in a patient who experienced possible drug-related thrombocytopenia previously received this drug and another histamine-2 (H2) receptor antagonist.[Ref]

Hepatic

Some patients developed ALT and/or AST elevations exceeding 500 international units/L, with a report of an ALT level exceeding 2000 international units/L.

Some patients 2 to 18 years developed mild elevations in serum transaminase levels (1 to 2 times the upper limit of normal).

Liver enzyme elevations and liver abnormalities were reversible upon discontinuation of treatment.[Ref]

Rare (0.01% to 0.1%): Transient, marked transaminase elevations, transient, marked alkaline phosphatase elevations

Frequency not reported: Elevated liver enzyme tests (alkaline phosphatase, ALT, AST), hepatocellular injury, transient, asymptomatic transaminase elevations, transient, asymptomatic alkaline phosphatase elevations

Postmarketing reports: Cholestatic injury, cholestatic injury with jaundice, hepatitis, jaundice, mixed hepatocellular injury, mixed hepatocellular injury with jaundice[Ref]

Hypersensitivity

Hypersensitivity reactions included bronchospasm, eosinophilia, laryngeal edema, and rash.[Ref]

Postmarketing reports: Anaphylaxis, hypersensitivity reactions[Ref]

Genitourinary

Postmarketing reports: Impotence[Ref]

Endocrine

Postmarketing reports: Gynecomastia[Ref]

References

1. Cerner Multum, Inc. Australian Product Information.

2. Product Information. Axid (nizatidine). Lilly, Eli and Company. 2002;PROD.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.